Tanvex BioPharma, Inc. (“Tanvex”), a contract development and manufacturing organization (CDMO) for biologics and a biosimilars products company, is pleased to announce the successful completion of its acquisition of Bora Biologics Co., Ltd. (“Bora Biologics”), a subsidiary of Bora Pharmaceuticals. Following this acquisition, Tanvex’s CDMO services will operate under the name Bora Biologics, continuing to be owned by Tanvex. This acquisition merges Tanvex’s expertise in biosimilar development and commercialization at its FDA-licensed commercial-scale facility in San Diego with Bora’s extensive global early-stage biologics CDMO capabilities in Taiwan, leveraging a proven track record of over 100 successful cGMP manufacturing batches.
Read the full article: Tanvex BioPharma Completes Acquisition of Bora Biologics, Launching New Era in Biologics Development //
Source: https://www.accessnewswire.com/newsroom/en/biotechnology/tanvex-biopharma-completes-acquisition-of-bora-biologics-launching-new-era-in-biologics-development-962970